en · de · es · pt
sr9009-notes.peptides9002.com › News › Sr9009 Background And Mechanism — 2026 Update

Sr9009 Background And Mechanism — 2026 Update

By Editorial Desk · published 2025-08-23 · last reviewed 2025-09-09 · News

LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Related pages on this site

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Notes from published material

==== Parkinson's disease ==== Creatine's impact on mitochondrial function has led to research on its efficacy and safety for slowing Parkinson's disease. As of 2014, the evidence did not provide a reliable foundation for treatment decisions, due to risk of bias, small sample sizes, and the short duration of trials.

== Biosynthesis == Kynurenine gives its name to the kynurenine pathway which leads from the amino acid tryptophan to many important enzyme cofactors including niacin and nicotinamide adenine dinucleotide.

Rhabdomyosarcoma: These are fast growing destructive swellings usually in the maxilla. It is the most common oral sarcoma in children and adolescents, but rare. Kaposi sarcoma: These are related to the Kaposi sarcoma herpes virus (KSHV) or human herpes virus (HHV-8) viral infection. Predominating on the hard palate and gingivae it develops initially as a macule ranging in colour from red, blue, purple to brown or black, becoming nodular as it grows. The lesions are highly vascular and can ulcerate and bleed easily; death is usually from opportunistic infections. It is usually associated with HIV/AIDS but also less commonly with immunosuppression such as organ donor recipients or prevalent in some communities such as Mediterranean Jews. There is no cure but the lesions respond well to highly active antiretroviral treatment (HAART) drugs.

Krebiozen (aka Carcalon, creatine, substance X, or drug X) is a disproven alternative cancer treatment. While the substance has been marketed as a cure for cancer, originally sold for thousands of dollars per dose in the 1950s and early '60s, Krebiozen is not known to possess any therapeutic value. Attempts to analyze this patent medicine have shown that Krebiozen consists only of the amino acid creatine dissolved in mineral oil, and some samples sold as Krebiozen consist solely of mineral oil with no other discernible ingredients. The American Cancer Society (ACS) states: "Available scientific evidence does not support claims that Krebiozen is effective in treating cancer or any other disease." ACS did not have data on safety but noted that "creatine supplements have been linked with some side effects."

== Research == György Kéri was an internationally recognized expert on signal transduction therapy and personalized therapy. His pioneering work focused on the utilization of signal transduction therapy approach in the pharmaceutical research. He achieved outstanding results in the research and development of peptide hormone derivatives and kinase inhibitors as antitumor agents. He was involved in the development of a signal-inhibiting somatostatin peptide compound (TT-232), which reached Phase II clinical trials, and SU101, which reached Phase III clinical trials. Vichem – the company he co-founded in 1999 – developed a kinase inhibitor library, and a hit finding technology called Nested Chemical Library™ technology and an allosteric library for inhibiting protein-protein interactions. He has developed at Vichem the DriverHit Library™ for inhibiting the signaling pathways activated by cancer driver genes or mutated tumor suppressor genes. He also participated with German researchers in the development of a new proteomic technology (Target Fishing technology) which makes it possible to identify unknown targets in the signal transduction network or the interacting enzymes of the metabolome. Over a hundred international patents or patent applications can be linked to his name, while he is a co-author of more than 250 publications in international scientific journals and several book chapters.

Sources: en.wikipedia.org

Further detail

=== CD200 === Basophil function is inhibited by CD200. Herpesvirus-6, herpesvirus-7, and herpesvirus-8 produce a CD200 homolog which also inhibits basophil function. This suggests that basophils may play a role in the immune response to these viruses. The role of basophils in the immune response to these viruses is further supported by findings that the CD200 receptor is expressed more frequently in basophils than in other circulating leukocytes.

=== Mass-balance equations === In general, the calculations are rather complicated or complex. For instance, in the case of a dibasic acid, H2A dissolved in water the two reactants can be specified as the conjugate base, A2−, and the proton, H+. The following equations of mass-balance could apply equally well to a base such as 1,2-diaminoethane, in which case the base itself is designated as the reactant A:

While this has been well known since the 19th century, an insistence on only monophyletic taxa has resulted in vertebrate classification being in a state of flux. The majority of animals more complex than jellyfish and other cnidarians are split into two groups, the protostomes and deuterostomes, the latter of which contains chordates. It seems very likely the 555 million-year-old Kimberella was a member of the protostomes. If so, this means the protostome and deuterostome lineages must have split some time before Kimberella appeared—at least 558 million years ago, and hence well before the start of the Cambrian 538.8 million years ago. Three enigmatic species that are possible very early tunicates, and therefore deuterostomes, were also found from the Ediacaran period – Ausia fenestrata from the Nama Group of Namibia, the sac-like Yarnemia ascidiformis, and one from a second new Ausia-like genus from the Onega Peninsula of northern Russia, Burykhia hunti. Results of a new study have shown possible affinity of these Ediacaran organisms to the ascidians. Ausia and Burykhia lived in shallow coastal waters slightly more than 555 to 548 million years ago, and are believed to be the oldest evidence of the chordate lineage of metazoans. The Russian Precambrian fossil Yarnemia is identified as a tunicate only tentatively, because its fossils are nowhere near as well-preserved as those of Ausia and Burykhia, so this identification has been questioned.

=== Marijuana === Similar to alcohol, marijuana is absorbed into the bloodstream and crosses the blood brain barrier. Notably, the THC released from marijuana binds to the CB-1 cannabinoid receptors, inducing various effects. These effects encompass mood changes, altered perception of time, and heightened sensitivity, among others.

=== Packaging === Food packaging technologies are used to extend the shelf-life of products, to stabilize food (preserve taste, appearance, and quality), and to maintain the food clean, protected, and appealing to the consumer. This can be achieved, for example, by packaging food in cans and jars. Because food production creates large amounts of waste, many companies are transitioning to eco-friendly packaging to preserve the environment and attract the attention of environmentally conscious consumers. Some types of environmentally friendly packaging include plastics made from corn or potatoes, bio-compostable plastic and paper products which disintegrate, and recycled content. Even though transitioning to eco-friendly packaging has positive effects on the environment, many companies are finding other benefits, such as reducing excess packaging material, helping to attract and retain customers, and showing that companies care about the environment.

Sources: en.wikipedia.org

Background from the literature

== 1979 incident == On December 26, 1979, after the family had come together for Christmas at their Newport, Rhode Island mansion, she was found unresponsive and was rushed to the hospital where she slipped into a coma, but was revived. After days of testing, doctors determined the coma was the result of low blood sugar and diagnosed her as hypoglycemic, warning her against overindulging on sweets or going too long without eating. While no foul play was suspected at the time, Claus von Bülow was later accused of causing this incident by injecting her with insulin. In April 1980, she was again hospitalized after appearing incoherent and disoriented; their doctors reconfirmed she suffered from reactive hypoglycemia. She was advised to maintain control of the hypoglycemia by following a strict diet, limiting her sugar intake, and avoiding alcohol.

=== Chronic exposures === The long-term toxicity of copper has not been well studied in humans, but it is infrequent in normal populations that do not have a hereditary defect in copper homeostasis. There is little evidence to indicate that chronic human exposure to copper results in systemic effects other than liver injury. Chronic copper poisoning leading to liver failure was reported in a young adult male with no known genetic susceptibility who consumed 30–60 mg/d of copper as a mineral supplement for 3 years. Individuals residing in U.S. households supplied with tap water containing >3 mg/L of copper exhibited no adverse health effects. No effects of copper supplementation on serum liver enzymes, biomarkers of oxidative stress, and other biochemical endpoints have been observed in healthy young human volunteers given daily doses of 6 to 10 mg/d of copper for up to 12 weeks. Infants aged 3–12 months who consumed water containing 2 mg Cu/L for 9 months did not differ from a concurrent control group in gastrointestinal tract (GIT) symptoms, growth rate, morbidity, serum liver enzyme and bilirubin levels, and other biochemical endpoints.) Serum ceruloplasmin was transiently elevated in the exposed infant group at 9 months and similar to controls at 12 months, suggesting homeostatic adaptation and/or maturation of the homeostatic response. Dermal exposure has not been associated with systemic toxicity but anecdotal reports of allergic responses may be a sensitization to nickel and cross-reaction with copper or a skin irritation from copper.

== See also == Outline of the Yemeni crisis, revolution, and civil war (2011–present) South Yemen insurgency COVID-19 pandemic in Yemen Yemen cholera outbreak Health in Yemen Famine in Yemen (2016-present)

=== Ovulation === NGF is abundant in seminal plasma. Recent studies have found that it induces ovulation in some mammals e.g. "induced" ovulators, such as llamas. Surprisingly, research showed that these induced animals will also ovulate when semen from on-schedule or "spontaneous" ovulators, such as cattle is used. Its significance in humans is unknown. It was previously dubbed ovulation-inducing factor (OIF) in semen before it was identified as beta-NGF in 2012.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network